Giiant Pharma
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
630 René-lévesque Boul. West Fl 20, Mont...Phone Number
(514) 924-1456Website
www.giiant.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Giiant Pharma
Giiant Pharma specializes in developing gut-restricted, small molecule therapeutics aimed at treating inflammatory bowel diseases (IBD). The company focuses on precision delivery to ensure limited systemic exposure while maximizing local action, thereby improving patient care and drug tolerability. Their innovative approach leverages the gut microbiota to bioactivate and release drugs specifically in the lower gastrointestinal tract. Giiant Pharma aims to lead in precision delivery technologies, providing safer, patient-tailored treatments for various gastrointestinal conditions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Giiant Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Giiant Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Giiant Pharma
Product Launch: Get notified when Giiant Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Giiant Pharma had a recent Job posting/layoffs
Check if Giiant Pharma has recently received funding, and reach out quickly before it becomes old news!
Giiant Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Giiant Pharma has new funding data
Check out if Giiant Pharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Giiant Pharma
Compare insights from companies similar to Giiant Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Giiant Pharma
<$5M
1-10
Private
$12.3M
2014
N/A
Company Profile Activity
Activity Insights
Giiant Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Giiant Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Giiant Pharma.
Giiant Pharma financials insights
Gather financial insights about Giiant Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$11M
Angel/Seed
$1.3M
Giiant Pharma Tech Stack
A closer look at the technologies used by Giiant Pharma
Giiant Pharma News & Media
Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation
MONTREAL--(BUSINESS WIRE)--Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000. This financing will support the development of GT-2108, an orally administered, gut-restricted, colon-specific PDE4 (phosphodiesterase-4) inhibitor prodrug for patients affected by moderate-to-severe ulcerative colitis. Giiant’s PGenesys Capital appoints Venture Partner
Genesys Capital appoints Venture Partner Submitted 14/01/2022 - 9:57am Genesys Capital has appointed Dr Maxime Ranger as a Venture Partner. Later this year, he will transition from this role into the role of General Partner of Genesys Ventures IV LP. Genesys has enjoyed a long-standing relationship with Ranger as he has co-created and provided leadership to three biopharma companies alongside Genesys over the past 15 years, including most recently having co-founded and currently serving asGiiant Pharma Inc annonce la nomination de Christophe Mellon, PhD au poste de Vice-président, découverte et chimie
MONTRÉAL--(BUSINESS WIRE)-- #canadianbiotech--Giiant Pharma Inc., une entreprise en biotechnologie développant une approche thérapeutique circonscrite au tube digestif au stade préclinique en gastro-entérologie, annonce l’expansion de son équipe de direction de la recherche, avec la nomination de Christophe Mellon, PhD. Le parcours riche et varié de Christophe l’a mené vers des positions de leadership dans les domaines de la pharmaceutique, des biotechnologies, et des start-ups au cours des 20 dGiiant Pharma Appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry
MONTREAL--(BUSINESS WIRE)-- #biotech--Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD. Christophe’s rich and varied career path led him to leadership positions in pharmaceutical, biotech, and start-up companies for more than 20 years. Recently, he had been appointed to lead a company in the material scienc
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Giiant Pharma
Sign Up For FreeTo access detailed company insights
Giiant Pharma specializes in developing gut-restricted, small molecule therapeutics aimed at treating inflammatory bowel diseases (IBD). The company focuses on precision delivery to ensure limited systemic exposure while maximizing local action, thereby improving patient care and drug tolerability. Their innovative approach leverages the gut microb... Read More
